BioAxis Research Home

Latest News

 

2020


Collaboration work continues with small biotechs, EU & US pharma, EU chemistry providers & screening centers, new work with UK charities


2019


Collaboration work continues with small biotechs, EU & US pharma, EU chemistry providers & EU screening centers


2018

 

Further publication on drug design workflows as part of 3D-e-Chem consortium work.

 

Collaboration work continues and now includes small biotechs, EU & US pharma, EU chemistry providers & EU screening centers

 

Q3-4 2017

 

The International Chemical Design Course at RadboudUMC has taken place, including lectures and hands-on KNIME practicals given by BioAxis Research and the 3D-e-Chem consortium.

 

Collaboration work continues and now includes small biotechs, EU & US pharma, EU chemistry providers & EU screening centers

 

Q2 2017

 

BioAxis Research has recieved subsidy funding for a project "Multi-Target Metabolic Syndrome Drugs" (STIMULUS funding, MKB Innovatiestimulering topsectoren Zuid-Nederland).

 

Collaboration work continues and now includes small biotechs, EU & US pharma, EU chemistry providers & EU screening centers

 

Q1 2017

 

The 3D-e-Chem consortium, a team of chem- and bioinformatics researchers [CMBI (Radboudumc), Netherlands eScience Center, BioAxis Research, and Vrije Universiteit Amsterdam] have developed an open source virtual machine for computer-aided drug design. Described in a recent publication,

the computational building blocks (nodes) that enable researchers to design their own drug discovery workflows are now incorporated in KNIME, the leading open data analytics platform.

 

Q4 2016

 

COILED collaboration funded by an EFRO grant begins








Collaboration work continues with small biotechs/large pharma/European screening centers


Q3 2016

 

3D-e-Chem VM and Knime nodes updated

 

Q1/Q2 2016

 

3d-e-Chem poster presented at Knime Spring Summit detailing progress on 3d-echem Virtual Machine and Knime nodes

 

New collaboration with pharma, others continue


Contact:

Tel  +31 (0)653589156

Visiting Address  RK1332| Pivot Park Oss | Molenstraat 110 | 5342 AC | Oss | The Netherlands

Postal Address   RK1332| Pivot Park Oss | Molenweg 79 | 5349 AC | Oss | The Netherlands

e-mail  contact@bioaxisresearch.com


Voorwaarden

Three Xanthines
Beclomethasone
Caffeine molecular orbitals
Rocuronium
Sabutamol Bound in 2Y04
PDB 2Y04
LXR-alpha, pdb 3IPQ

BioAxis Research


Key Activities


BioAxis Research offers


  • Collaborative research to identify leads and develop drug candidates
  • Cheminformatics, molecular property calculations, data mining
  • Structure, Fragment-based drug design, Computational Medicinal Chemistry
  • Combined data, text and network mining, association analyses


Expertise


Strong Pharma Background in industry-leading cheminformatics and compound analysis. We help clients progress early stage discovery activities, working collaboratively to implement in silico drug design techniques, maximizing the potential of compounds to reach later development stages.

Our expertise covers:


  • Compound collection analyses and library design
  • Structure-activity relationships
  • Multiparameter compound optimization
  • Compound progressibility analyses


Capabilities


Our success relies on secure professional collaboration, solid experience in pharmaceutical research and the most up-to-date computational tools.


A variety of applications are available covering Pharma and non-Pharma research. Our expertise ranges from industry leading commercially licensed molecular modelling suites, to open source workflow systems and relational databases.



Copyright © 2011-2020 All Rights Reserved